Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MDGL |
---|---|---|
09:32 ET | 2063 | 220.595 |
09:34 ET | 100 | 219.9 |
09:39 ET | 100 | 222.84 |
09:41 ET | 300 | 220.29 |
09:43 ET | 600 | 219.99 |
09:45 ET | 300 | 219.84 |
09:52 ET | 300 | 220.455 |
09:54 ET | 200 | 221.64 |
09:56 ET | 529 | 221.72 |
09:59 ET | 1400 | 221.485 |
10:01 ET | 2200 | 221.755 |
10:03 ET | 100 | 221.775 |
10:12 ET | 200 | 222.155 |
10:14 ET | 100 | 221.86 |
10:17 ET | 271 | 221.06 |
10:19 ET | 205 | 220.86 |
10:21 ET | 650 | 220.2 |
10:24 ET | 1905 | 219.935 |
10:26 ET | 601 | 220.495 |
10:28 ET | 160 | 221.105 |
10:32 ET | 209 | 220.7 |
10:33 ET | 1030 | 220.46 |
10:35 ET | 499 | 221.45 |
10:37 ET | 1700 | 221.99 |
10:39 ET | 160 | 222.0407 |
10:42 ET | 150 | 221.665 |
10:46 ET | 600 | 222.385 |
10:48 ET | 200 | 222.61 |
10:50 ET | 100 | 222.965 |
10:53 ET | 100 | 223.63 |
11:00 ET | 300 | 223.5 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Madrigal Pharmaceuticals Inc | 4.8B | -9.7x | --- |
Immunitybio Inc | 4.6B | -6.1x | --- |
Nuvalent Inc | 4.3B | -27.2x | --- |
BridgeBio Pharma Inc | 5.2B | -8.5x | --- |
Krystal Biotech Inc | 4.5B | 82.9x | --- |
Immunovant Inc | 4.1B | -16.7x | --- |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.8B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 21.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.42 |
EPS | $-23.08 |
Book Value | $20.39 |
P/E Ratio | -9.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.